CBD disrupts cancer protein complex in promising lab study

Researchers have developed a groundbreaking technique called stability- and degradation-based proteome profiling (SDPP) to identify how natural products like cannabidiol (CBD) work at the molecular level. Using this method, they discovered that CBD acts as a protein-protein interaction inhibitor, specifically disrupting the CDC123-eIF2γ complex in cancer cells. This disruption triggers a sustained integrated stress response that leads to programmed cell death (apoptosis) in colorectal cancer cells. The study identifies CDC123 as an oncogenic driver in colorectal cancer, meaning it promotes cancer growth, and patients with elevated CDC123 expression have significantly worse prognoses.

The findings position CBD as a first-in-class natural protein-protein interaction inhibitor with specific therapeutic potential for colorectal cancer treatment. Unlike traditional drugs that target single proteins, CBD appears to work by preventing two cancer-promoting proteins from binding together, offering a selective therapeutic strategy that may reduce side effects. This represents a novel mechanism of action for CBD beyond its known effects on pain, anxiety, and inflammation, and opens new possibilities for cannabis-derived compounds in oncology. The SDPP technique itself may accelerate future drug discovery from natural products by making it easier to identify their molecular targets.